GLP-1 Drug Revolution: Surge, Supply, Coverage, Safety, and New Uses

GLP-1 medicines continue reshaping obesity and diabetes care through tirzepatide’s cardiovascular indication, heart-failure guidance, pediatric semaglutide results, and emerging oral and multi-agonist therapies. New dose-comparison data favor higher-dose orforglipron for efficacy, but pulse, liver-enzyme, long-term safety, durability, tolerability, and access questions remain. Newly reviewed oral Wegovy and Novo Nordisk growth claims are largely company-reported and add no independent clinical evidence; resistance training, individualized protein, functional outcomes, and maintenance planning remain central.